People · Operator
Named in public records as an officer, director or promoter · active 2010–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Maverick Therapeutics Inc. | — | Biotechnology | Series C | $56.0M | $2.3B | 2017 |
| Bioscale Inc | — | Biotechnology | Series B | $44.7M | $747.7M | 2010 |
| Rekindle Therapeutics Inc. | — | Biotechnology | Seed | $1.1M | $48.8M | 2018 |
Bard Geesaman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bard Geesaman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Somu Subramaniam | 1 | 17 |
| Luke Evnin | 1 | 12 |
| Isaac Cheng | 1 | 9 |
| Ed Hurwitz | 1 | 9 |
| William F. Doyle | 1 | 8 |
| Paul Billings | 1 | 5 |
| Detlev Biniszkiewicz | 1 | 4 |
| William Doyle | 1 | 4 |
| Edward Crawley | 1 | 4 |
| BARD J. GEESAMAN | 1 | 3 |
| Bill Doyle | 1 | 2 |
| Edward F. Crawley | 1 | 2 |
| Isaac S. Cheng | 1 | 2 |
| Lori Kunkel | 1 | 2 |
| Somu Subramanian | 1 | 2 |
| Brett E. Masters | 1 | 1 |
| Riccardo Pigliucci | 1 | 1 |
| Mark Lundstrom | 1 | 1 |
| Mark E. Lundstrom | 1 | 1 |
| Dan Hicklin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.